Medicare’s Independent Payment Advisory Board: First, Do No Harm
This article was originally published in RPM Report
The Affordable Care Act promises some important improvements in the US healthcare system. However, argues a biotech CEO, cutting spending by targeting the lifeblood of biopharma R&D is not one of them.
You may also be interested in...
Competition and a focus on effectiveness rather than price will lower America’s healthcare bill.